

BIOGEN IDEC INC.
Form 4
March 12, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
PAPADOPOULOS STELIOS

(Last) (First) (Middle)

BIOGEN IDEC INC., 133 BOSTON POST ROAD

(Street)

WESTON, MA 02493

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [BIIB]

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2013		M ⁽¹⁾		35,000	A	\$ 59.17
							49,950
Common Stock	03/11/2013		S ⁽¹⁾		31,034	D	\$ 172.081
							(2) (3)
Common Stock	03/11/2013		S ⁽¹⁾		3,966	D	\$ 172.723
							(2) (4)
Common Stock	03/11/2013		M ⁽¹⁾		5,700	A	\$ 59.17
							20,650
	03/11/2013		S ⁽¹⁾		5,700	D	14,950
							D

Edgar Filing: BIOGEN IDEC INC. - Form 4

Common Stock						\$		
						172.446		
						<u>(2)</u> <u>(5)</u>		
Common Stock	03/11/2013		M ⁽¹⁾	5,975	A	\$ 53.43	20,925	D
Common Stock	03/11/2013		S ⁽¹⁾	5,975	D	\$		
						172.666	14,950	D
						<u>(2)</u> <u>(6)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy) ⁽⁷⁾	\$ 59.17	03/11/2013		M ⁽¹⁾	35,000	<u>(8)</u>	06/18/2018	Common Stock	35,000
Stock Option (Right to Buy) ⁽⁷⁾	\$ 59.17	03/11/2013		M ⁽¹⁾	5,700	06/19/2009	06/18/2018	Common Stock	5,700
Stock Option (Right to Buy) ⁽⁷⁾	\$ 53.43	03/11/2013		M ⁽¹⁾	5,975	06/03/2010	06/02/2019	Common Stock	5,975

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

PAPADOPOULOS STELIOS
BIOGEN IDEC INC. X
133 BOSTON POST ROAD
WESTON, MA 02493

Signatures

Robert A. Licht, Attorney in Fact for Stelios
Papadopoulos

03/12/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (3) This represents the weighted average price for shares sold at a range between \$171.68 (low) and \$172.68 (high).
- (4) This represents the weighted average price for shares sold at a range between \$172.68 (low) and \$172.79 (high).
- (5) This represents the weighted average price for shares sold at a range between \$171.80 (low) and \$172.75 (high).
- (6) This represents the weighted average price for shares sold at a range between \$172.59 (low) and \$172.75 (high).
- (7) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).
- (8) The stock options become exercisable in three (3) equal annual installments, commencing one year after the grant date of 06/19/2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.